Annemijn D. I. Maan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annemijn D. I. Maan has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Arjun Dave Koch
Erasmus MC Cancer Institute, Netherlands
4 shared publications Arjun D. Koch
2 shared publications- A. Sewnaik1 shared publication
Alanna Ebigbo
St. Josef-Hospital Bochum, Ruhr University Bochum, Germany
1 shared publicationB. Mostert
1 shared publicationBenjamin M. Walter
University Hospital Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands
- 20 July 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Open AccessIncidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands
- Open Access
- 7 July 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (11) , 1199-1210
Technical and clinical success of endoscopic hand-suturing: a European multicenter study
Endoscopic closure techniques are essential for management of endoscopic defects and help prevent delayed bleeding and perforation. This study reports clinical outcomes of an endoscopic hand-suturing system (EHS) for defect closure. This multicenter European registry study evaluated all procedures using EHS from 14 centers. The primary end point was technical success, defined as complete defect closure without additional closure techniques. Secondary end points were in-hospital clinical success (absence of post-interventional complications), overall defect closure rate (closure achieved with additional devices), and suturing speed. Between February 2023 and January 2026, 338 procedures were included. Indications comprised endoscopic submucosal dissection (n = 240), endoscopic intermuscular dissection (n = 32), gastric peroral endoscopic myotomy (n = 41), fistula (n = 10), endoscopic mucosal resection (n = 6), submucosal tunneling endoscopic resection (n = 3), nonexposed endoscopic wall inversion surgery (n = 2), and anastomotic leak, perforation, endoscopic full-thickness resection, and endoscopic hemostasis (all n = 1). Median defect size was 35 mm (range 4–155 mm) and median suturing time was 25 minutes (range 4–120). Technical success was 96.2% (325/338). Overall defect closure rate was 96.7% (327/338). In-hospital clinical success was 97.9% (331/338). Defect size did not predict suturing time in the size-adjusted model, indicating that procedural complexity was not explained by size alone. Procedure-related adverse events occurred in 5/338 (1.5%); overall adverse event rate was 10/338 (3.0%). EHS demonstrated high technical and in-hospital clinical success with a low short-term adverse event rate. Further studies are needed to assess performance with complex defects.
- 7 July 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (11) , 1199-1210
Open AccessTechnical and clinical success of endoscopic hand-suturing: a European multicenter study
Endoscopic closure techniques are essential for management of endoscopic defects and help prevent delayed bleeding and perforation. This study reports clinical outcomes of an endoscopic hand-suturing system (EHS) for defect closure. This multicenter European registry study evaluated all procedures using EHS from 14 centers. The primary end point was technical success, defined as complete defect closure without additional closure techniques. Secondary end points were in-hospital clinical success (absence of post-interventional complications), overall defect closure rate (closure achieved with additional devices), and suturing speed. Between February 2023 and January 2026, 338 procedures were included. Indications comprised endoscopic submucosal dissection (n = 240), endoscopic intermuscular dissection (n = 32), gastric peroral endoscopic myotomy (n = 41), fistula (n = 10), endoscopic mucosal resection (n = 6), submucosal tunneling endoscopic resection (n = 3), nonexposed endoscopic wall inversion surgery (n = 2), and anastomotic leak, perforation, endoscopic full-thickness resection, and endoscopic hemostasis (all n = 1). Median defect size was 35 mm (range 4–155 mm) and median suturing time was 25 minutes (range 4–120). Technical success was 96.2% (325/338). Overall defect closure rate was 96.7% (327/338). In-hospital clinical success was 97.9% (331/338). Defect size did not predict suturing time in the size-adjusted model, indicating that procedural complexity was not explained by size alone. Procedure-related adverse events occurred in 5/338 (1.5%); overall adverse event rate was 10/338 (3.0%). EHS demonstrated high technical and in-hospital clinical success with a low short-term adverse event rate. Further studies are needed to assess performance with complex defects.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Annals of Laparoscopic and Endoscopic Surgery
- Vol. 11, 10
T1b esophageal cancer: upstaging, the price of oncological certainty, and personalization
T1b esophageal cancer: upstaging, the price of oncological certainty, and personalization
- 1 April 2026
- Published by AME Publishing Company in Annals of Laparoscopic and Endoscopic Surgery
- Vol. 11, 10
Open AccessT1b esophageal cancer: upstaging, the price of oncological certainty, and personalization
T1b esophageal cancer: upstaging, the price of oncological certainty, and personalization
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Comparison of Primary Endoscopic Submucosal Dissection versus Primary Endoscopic Mucosal Resection for Barrett’s Esophageal Neoplasia Treatment
Background Endoscopic resection of Barrett’s esophageal neoplasia is commonly performed using either endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR). While submucosal dissection enables en bloc resection, institutional approaches vary. We compared clinical, histopathologic, and oncologic outcomes between a primary submucosal dissection strategy and a mucosal resection-based strategy with selective use of submucosal dissection. Methods This retrospective cohort study included all patients with Barrett’s esophageal neoplasia treated at two European tertiary referral centers. At Karolinska University Hospital, the primary submucosal dissection strategy was adopted, whereas at Erasmus Medical Center the mucosal resection-based strategy was employed. Patients with prior endoscopic therapy or hematologic disorders were excluded. Primary outcomes were local recurrence, synchronous and metachronous lesions prior to ablation, and cancer- or treatment-related mortality. Secondary outcomes included resection quality, adverse events, and the need for repeated resections. Time-to-event analyses were performed using Kaplan–Meier and Cox regression models. Results A total of 332 patients were included (132 in the primary submucosal dissection group and 200 in the mucosal resection–based group). En bloc resection was more frequent with the primary submucosal dissection strategy (98.5% vs 40.0%, p < 0.001). Compared with the EMR-based strategy, the pESD strategy was associated with significantly lower local recurrence (3.0% vs 10.0%, p = 0.02) and fewer resection sessions per patient, whereas rates of synchronous and metachronous lesions were similar between groups. Adverse events and cancer- or treatment-related mortality did not differ between strategies. Conclusions Both strategies are safe. However, the primary submucosal dissection strategy is associated with lower local recurrence and fewer resection sessions.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Open AccessComparison of Primary Endoscopic Submucosal Dissection versus Primary Endoscopic Mucosal Resection for Barrett’s Esophageal Neoplasia Treatment
Background Endoscopic resection of Barrett’s esophageal neoplasia is commonly performed using either endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR). While submucosal dissection enables en bloc resection, institutional approaches vary. We compared clinical, histopathologic, and oncologic outcomes between a primary submucosal dissection strategy and a mucosal resection-based strategy with selective use of submucosal dissection. Methods This retrospective cohort study included all patients with Barrett’s esophageal neoplasia treated at two European tertiary referral centers. At Karolinska University Hospital, the primary submucosal dissection strategy was adopted, whereas at Erasmus Medical Center the mucosal resection-based strategy was employed. Patients with prior endoscopic therapy or hematologic disorders were excluded. Primary outcomes were local recurrence, synchronous and metachronous lesions prior to ablation, and cancer- or treatment-related mortality. Secondary outcomes included resection quality, adverse events, and the need for repeated resections. Time-to-event analyses were performed using Kaplan–Meier and Cox regression models. Results A total of 332 patients were included (132 in the primary submucosal dissection group and 200 in the mucosal resection–based group). En bloc resection was more frequent with the primary submucosal dissection strategy (98.5% vs 40.0%, p < 0.001). Compared with the EMR-based strategy, the pESD strategy was associated with significantly lower local recurrence (3.0% vs 10.0%, p = 0.02) and fewer resection sessions per patient, whereas rates of synchronous and metachronous lesions were similar between groups. Adverse events and cancer- or treatment-related mortality did not differ between strategies. Conclusions Both strategies are safe. However, the primary submucosal dissection strategy is associated with lower local recurrence and fewer resection sessions.
- Open Access
- 6 April 2025
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 8
Screening for second primary tumors in the aerodigestive tract in non-Asian populations with head and neck cancer – systematic review and meta-analysis
- 6 April 2025
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 8
Open AccessScreening for second primary tumors in the aerodigestive tract in non-Asian populations with head and neck cancer – systematic review and meta-analysis
- Open Access
- 5 February 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 75, 101984
Increased risk of oesophageal squamous cell carcinoma development
- 5 February 2025
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 75, 101984
Open AccessIncreased risk of oesophageal squamous cell carcinoma development